EAACI Allergopharma Award

About

The EAACI Allergopharma Research Award was first established in 2000 on the initiative of Allergopharma Joachim Ganzer KG in collaboration with the European Academy of Allergy and Clinical Immunology. It is intended that the award should recognise scientific achievement of young scientists working in the field of allergy and encourage their engagement in further research. Therefore, the award is open to EAACI Junior Members who have conducted their research in a European centre. More information on EAACI Junior Members you will find by clicking here. (“EAACI Junior Membership shall be available to all those who are aged 35 years or less at the time of renewal of their subscription.”)

The award is valued at EUR 10,000 and will be granted to the institution or research organisation the awardee primarily conducts the research for. The awardee will be presented with the EAACI Allergopharma Research Award during the Opening Ceremony of the EAACI Annual Congress each year. Registration to the congress will be supported by the grant.

Applications open for EAACI Allergopharma Award 2026: September, 2025

General Guidelines

1. Any EAACI Junior Member (JM) may apply personally for the award using the online system provided.
2. Applicants can modify the author information, category and core data of their abstract directly in the submission system until the deadline was given. Please be aware that there will be no extension possible.
3. By submitting this application, I understand that my application, including names, is stored electronically.
4. Applications will be reviewed by an expert panel of reviewers. Acceptance of the submitted application is at the discretion of the Review Panel. Allergopharma will not be involved or take any influence on the decision-making process.
5. Declaration of Conflict of Interest: EAACI is committed to ensuring the integrity of its scientific, educational, and research programmes. Applications require disclosure of any financial or other interest that might be construed as resulting in an actual, potential, or apparent conflict.

Application procedure

1. Motivation letter/Executive summary: A summary of the applicant’s major accomplishments highlighting their impact on the field

2. A complete curriculum vitae

3. List of up to three individual articles that support the quality and originality of the research clearly identifying the concept(s) developed

4. Upload of 1 to 3 most relevant publications in PDF format

5. A complete bibliography of publications with key publications identified. In case of multiple authors, the applicant’s specific contribution to the publication should be briefly discussed

6. Cumulative citation factor and Impact factor

7. At least two supporting letters, at least one of which should be provided by a supporter outside the applicant’s institution. The letters should specifically support the significant accomplishments of the applicant justifying why the applicant should receive this recognition.

Selection Procedure

1. The received complete applications will be reviewed by EAACI’s independent scientific award committee.
Please note: For reasons of industry compliance, Allergopharma will not be involved in any way in the selection process.

2. The EAACI Executive Committee selects the awardee in February 2026.

3. Notification of the winner is in late February and the official announcement is during the Opening Ceremony of the EAACI Annual Congress 2026, in Istanbul. The prize money will be paid to the winner’s home institution by the end of July 2026.

Contact

For more information please contact:

EAACI Headquarters
Hagenholzstrasse 111
3rd Floor
8050 Zurich
Switzerland
Telephone: +41 44 205 55 33
E-mail: awards@eaaci.org